- Conditions
- FXI
- Interventions
- FXI-GalNAc-siRNA, Placebo
- Drug · Other
- Lead sponsor
- Sirnaomics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Creve Coeur, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–20
of 20
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Peripheral Artery Disease (PAD)
- Interventions
- REGN7508, REGN9933, Placebo, Rivaroxaban
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 27
- States / cities
- Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 23 more
- Conditions
- Stroke
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- End Stage Renal Disease Requiring Hemodialysis
- Interventions
- Fesomersen sodium (BAY2976217), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 9
- States / cities
- Clovis, California • Victorville, California • Fort Lauderdale, Florida + 5 more
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- REGN7508, Apixaban
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Hialeah, Florida • New York, New York • El Paso, Texas
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- REGN7508, REGN9933, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • Glendale, Arizona • Little Rock, Arkansas + 37 more
- Conditions
- Lymphoma, Malignant Solid Neoplasm, Plasma Cell Myeloma
- Interventions
- Xisomab 3G3
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Interventions
- Abelacimab, Apixaban
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 23
- States / cities
- Aurora, Colorado • West Haven, Connecticut • Washington D.C., District of Columbia + 19 more
- Conditions
- Thrombosis, Factor XI, Renal Impairment, ESRD (End-Stage Renal Disease)
- Interventions
- BMS-986177
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- REGN7508, Apixaban, Enoxaparin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Sheffield, Alabama • Riverside, California • Englewood, Colorado + 16 more
- Conditions
- Cancer-Associated Thrombosis (CAT)
- Interventions
- REGN7508, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Hialeah, Florida • North Miami Beach, Florida • New York, New York + 1 more
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Interventions
- MK-2060, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 77
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
- Conditions
- Venous Thromboembolism
- Interventions
- REGN9933, REGN7508, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 2 more
- Conditions
- Symptomatic Venous Thromboembolism (VTE)
- Interventions
- REGN7508, Acetylsalicylic Acid (ASA), Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 38
- States / cities
- La Mesa, California • Rancho Mirage, California • Riverside, California + 30 more
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Interventions
- Abelacimab, Dalteparin
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Evanston, Illinois • St Louis, Missouri + 6 more
- Conditions
- Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage, Surgery
- Interventions
- Hemoleven
- Biological
- Lead sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Industry
- Eligibility
- 6 Months and older
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- REGN7508, Apixaban, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 49
- States / cities
- Alexander City, Alabama • Dothan, Alabama • Fairhope, Alabama + 44 more
- Conditions
- Post-thrombotic Syndrome, Deep Vein Thrombosis Leg
- Interventions
- Rosuvastatin
- Drug
- Lead sponsor
- Khanh Nguyen
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- REGN7508, REGN9933, Apixaban
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • Fairhope, Alabama • Covina, California + 36 more
- Conditions
- Atrial Fibrillation (AF), Stroke
- Interventions
- Abelacimab, Rivaroxaban
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more